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Percutaneous Transportal Sclerotherapy
with N-Butyl-2-Cyanoacrylate for Gastric
Varices: Technique and Clinical Efficacy
Objective: This study was deigned to evaluate the technique and clinical effica-
cy of the use of percutaneous transportal sclerotherapy with N-butyl-2-cyanoacry-
late (NBCA) for patients with gastric varices.
Materials and Methods: Seven patients were treated by transportal sclerother-
apy with the use of NBCA. For transportal sclerotherapy, portal vein catheteriza-
tion was performed with a 6-Fr sheath by the transhepatic approach. A 5-Fr
catheter was introduced into the afferent gastric vein and a microcatheter was
advanced through the 5-Fr catheter into the varices. NBCA was injected through
the microcatheter in the varices by use of the continuous single-column injection
technique. After the procedure, postcontrast computed tomography (CT) was
performed on the next day and then every six months. Gastroendoscopy was
performed at one week, three months, and then every six months after the proce-
dure.
Results: The technical success rate of the procedure was 88%. In six patients,
gastric varices were successfully obliterated with 1-8 mL (mean, 5.4 mL) of a
NBCA-Lipiodol mixture injected via a microcatheter. No complications related to
the procedure were encountered. As seen on the follow-up endoscopy and CT
imaging performed after six months, the presence of gastric varcies was not seen
in any of the patients after treatment with the NBCA-Lipiodol mixture and the use
of microcoils. Recurrence of gastric varices was not observed during the follow-
up period. Worsening of esophageal varices occurred in four patients after trans-
portal sclerotherapy. The serum albumin level increased, the ammonia level
decreased and the prothrombin time increased at six months after the procedure
(p < 0.05).
Conclusion: Percutaneous transportal sclerotherapy with NBCA is useful to
obliterate gastric varices if it is not possible to perform balloon-occluded retro-
grade transvenous obliteration.
astric fundal varices are less common than esophageal varices.
Esophageal varices occur in approximately 20% of patients with portal
hypertension (1). However, patients with bleeding from gastric fundal
varices have a poor prognosis and have more severe blood loss, a higher rebleeding
rate and a higher mortality rate (1-3). Endoscopic treatment is an alternative for the
management of gastric varices with hemorrhage and includes the use of endoscopic
injection of sclerosants or thrombin, endoscopic band ligation and the use of other
agents (4, 5). However, gastric fundal varices cannot be treated effectively with
endoscopic injection sclerotherapy due to systemic embolization and incomplete
embolization by the rapid loss of the sclerosing agent because of fast blood flow (1, 6-
9).
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GA transjugular intrahepatic portosystemic shunt (TIPS)
has been used for the treatment of gastric fundal varices.
The use of a TIPS is less invasive than the use of a surgical
shunt, and the TIPS mortality rate (1%) is lower than the
mortality rate for the use of surgical shunts (3-15%) (10,
11). However, the use of a TIPS does not always result in
regression of gastric fundal varices (12) and its use has not
been recommended in patients with hepatic encephalopa-
thy (13, 14).
Recently, balloon-occluded retrograde transvenous
obliteration (BRTO) through a gastrorenal shunt has been
recognized as a safe and effective treatment for gastric
varices (15-23). However, some cases of gastric varices
without catheterizable main draining veins cannot be
treated by the use of BRTO. Percutaneous transportal
sclerotherapy has been recently introduced for the
treatment of gastric varices without gastrorenal shunts
(24), and satisfactory treatment results have been reported
for patients. The present study was performed to evaluate
the clinical efficacy and technique associated with the use
of percutaneous transportal sclerotherapy of gastric varices
without a gastrorenal shunt.
MATERIALS AND METHODS
Patients
Between January 2005 and March 2007, 31 patients
with gastric varices who provided written informed
consent were referred to our department for treatment
with BRTO. Of these patients, 24 underwent the BRTO
procedure through a gastrorenal shunt. Seven patients (six
men and one woman; age range: 50-69 years; mean age,
57 years) underwent percutaneous transportal sclerother-
apy. Of these patients, six patients did not have catheteriz-
able draining veins through a systemic vein and one
patient received percutaneous transhepatic sclerotherapy
after failure of BRTO due to rupture of the gastrorenal
shunt. The clinical features of the seven patients are
summarized in Table 1. The underlying hepatic pathologies
were cirrhosis caused by hepatitis B virus in four patients,
cirrhosis caused by hepatitis C virus in one patient and
alcoholic cirrhosis in two patients. As seen on endoscopy,
six patients had active bleeding (spurting or oozing) from
the gastric fundal varices or showed signs of recent
bleeding, such as a clot or fibrin, and had esophageal
varices.
Technique
All of the patients were given intramuscular administra-
tion of atropine sulfate. All of the patients received local
anesthesia that consisted of an intramuscular injection of
lidocaine (Jeil Pharm, Taegu, Korea) as well as intravenous
sedation (Demerol; Keukdong Pharm, Seoul, Korea).
Ultrasonography (US) of the liver was performed to
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Table 1. Clinical Features of Seven Patients
Patient Age/Sex
Cause of Liver 
Location Bleeding Child’s Grade Esophageal Varix Draining Vein
Cirrhosis
1 52/M Viral (hepatitis C) Fundus + B + Paraesophageal
2 50/M Viral (hepatitis B) Fundus + A + Paraesophageal
3 69/M Alcoholic Fundus + B + Pericardiophrenic
4 57/F Viral (hepatitis B) Fundus - A - Paraesophageal
5 65/M Viral (hepatitis B) Fundus + B + Paraesophageal
6 59/M Alcoholic Fundus + A + Paraesophageal
7 50/M Viral (hepatitis B) Fundus + A + Paraesophageal
Table 2. Technical Results of Seven Patients
Patient Afferent Veins
Coil Embolization NBCA Embolization Results Worsening 
Draining Afferent Mixture (mL) Session Initial Six Months of EV
1 PG, SG, LG + + 6 6 Complete Complete -
2L G - + 7 6 Complete Complete +
3 PG, SG, LG + + 5 4 Partial Complete +
4S G -- 1 1 Complete Complete +
5 LG, PG + + 8 4 Complete Complete -
6 LG, SG + - 3 3 Complete Complete -
7L G - + 8 5 Complete Complete +
Note.─ NBCA = N-butyl-2-cyanoacrylate, EV = esophageal varix, PG = posterior gastric vein, SG = short gastric vein, LG = left gastric veindetermine the best access route into the portal venous
system. Under sterile conditions, access into the portal
venous system was gained under US or fluoroscopic
guidance, or both. The procedure was always performed
under fluoroscopy. Percutaneous transhepatic puncture of
the right intrahepatic porto-hepatic vein was performed
using a 21-gauge Chiba needle (Cook, Bloomington, IN)
under ultrasonographic and fluoroscopic guidance. The
needle was exchanged for a 4-Fr coaxial dilator and a 6-Fr
sheath (Cook) that were placed over either a 0.018-inch
guide wire (Cook) or a 0.035-inch angled hydrophilic guide
wire (Terumo, Tokyo, Japan). The 0.035-inch guide wire
and a 5-Fr cobra catheter (Cook) were used to traverse the
gastric varices. Splenoportography was performed with a
5-Fr catheter to evaluate the afferent gastric veins and
drainage veins. The main afferent gastric vein was selected
with a 5-Fr catheter and venography was performed to
access the varices. In four patients, a microcatheter was
advanced through the varices into the drainage vein, and
microcoils (Cook) were placed into the drainage vein for
reduction of venous flow. In five patients, a microcatheter
was advanced into the afferent vein and microcoils were
placed into the afferent vein to prevent recanalization. In
all patients, a 25% mixture of N-butyl-2-cyanoacrylate,
(NBCA) and Lipiodol was injected through the
microcatheter with its tip in the varices by use of a continu-
ous single-column injection technique until all of the
varices were opacified with the mixture. The microcatheter
Kwak et al.
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Fig. 1. 50-year-old man with gastric varices.
A. Contrast-enhanced CT scan shows gastric fundal varices (arrows) without portosystemic shunts (not shown). Note insertion of
Sengstaken-Blakemore tube into esophagus and stomach due to active hemorrhage (open arrows).
B. Percutaneous transportal portogram shows gastric varices (arrows) draining into paraesophageal veins (not shown).
C. After 5-Fr catheter was placed into left gastric vein, NBCA-Lipiodol mixture was injected via six microcatheters. Three coils were
placed in afferent veins after complete filling of NBCA-Lipiodol mixture into gastric varices.
D. Follow-up CT scan obtained six months later shows complete obliteration of varices (arrows).
CDwas withdrawn rapidly. After NBCA injection, venogra-
phy was performed with a 5-Fr catheter. When residual
varices remained, as visualized on venography, then an
additional embolization procedure with NBCA was
performed. Splenoportography with a 5-Fr catheter was
performed to ascertain if obliteration of the gastric varices
occurred and if enlargement of other afferent veins
occurred after obliteration of the main afferent vein. Four
patients were seen with filling of the gastric varices by the
additional afferent veins and the patients underwent
NBCA injection into the varices. When the transhepatic
approach was used, the 6-Fr sheath system was withdrawn
after embolization of the needle tract with the microcoils.
Follow-Up
After the procedure, postcontrast computed tomography
(CT) was performed on the next day and then every six
months. Gastroendoscopy was performed at one week,
three months and then every six months after the
procedure. In addition, hepatic function and blood cell
counts were monitored during the follow-up period. A
plain chest PA X-ray was obtained for each day during the
hospital stay to detect a distal embolization of the
pulmonary artery.
Technical success was defined as complete clotting of the
gastric varices as observed on CT images in the portal
phase on the day following treatment. Endoscopic and CT
findings of gastric varices, hepatic function tests including
measurement of the levels of serum albumin, bilirubin,
ammonia, prothrombin time and the presence of symptoms
were evaluated after the treatment. Significant differences
in the hepatic function tests before and after treatment
were determined by use of the Student’s t test. A p value
of less than 0.05 was considered as statistically significant.
RESULTS
Percutaneous transportal sclerotherapy with the use of
an NBCA-Lipiodol mixture was technically successful in
six patients (85.7%), including in one patient where the
procedure was performed after failure of BRTO. The
technical results are shown in Table 2. The number of
obliterations of the afferent vein was one in three patients,
two in two patients and three in two patients. The volume
of the injected NBCA-Lipiodol mixture ranged from 1 to 8
mL (mean, 5.4 mL). The number of procedures using the
NBCA-Lipiodol mixture through microcatheter ranged
from one to six sessions (mean, 4.2 sessions). As seen on
venography performed after the procedure, six patients
had complete obliteration of the gastric fundal varices with
use of the NBCA-Lipiodol mixture (Fig. 1). One patient
with a large pericardiophrenic draining vein experienced
incomplete filling of the NBCA-Lipiodol mixture into the
gastric varices. However, a large pericardiophrenic
draining vein and multiple afferent veins were completely
obliterated after use of the microcoils and the NBCA-
Lipiodol mixture. Final venography did not show contrast
filling into the gastric varices and draining vein (Fig. 2). No
complications associated with percutaneous transportal
sclerotherapy were encountered. In all of the patients,
follow-up CT imaging performed after six months showed
complete obliteration of the varices by the NBCA-Lipiodol
mixture or by formation of thrombi. Plain chest PA X-rays
did not detect any pulmonary artery embolization of the
NBCA-Lipiodol mixture during follow-up.
In all patients, neither recurrent gastric varices nor
variceal bleeding was observed during the follow-up
period of 7 to 21 months (mean, 14.8 months).
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Table 3. Clinical Results of Seven Patients
Patient
Ascites
1 Pleural Effusion
1 Child-Pugh Score
2 Bilirubin
2 PT (%)
2 Albumin
2 Ammonia
2
Before  After Before After Before After Before After Before After Before After Before After
1 ---- 8 7 3.83 2.93 49.4 54.3 3.8 2.9 51 27
2 ---- 6 5 1.05 0.63 51.3 69.4 3.0 4.6 47 31
3+ -- 8 7 1.60 1.99 52.9 61.3 2.6 3.4 91 59
4 ---- 5 5 1.10 0.47 100 96.0 4.1 4.7 76 20
5 - + - + 8 8 3.70 0.51 63.9 86.9 3.2 3.8 28 29
6 ---+ 5 5 1.07 0.94 75.1 86.6 3.6 3.7 84 34
7 ---- 6 5 1.11 0.65 50.5 71.5 2.8 3.8 51 32
Mean 6.7 6.2 2.06 1.25 65.4 75.9 3.3 3.7 62.8 33.3
SD 1.5 1.3 1.27 0.94 18.7 15.3 0.5 0.5 22.9 12.3
p 0.1 0.01* 0.01* 0.009*
Note.─ PT = prothrombin time, SD = standard deviation, *Statistically significant as compared with each value before treatment (p < 0.05).
1Changes of ascites and pleural effusion after one week.
2Changes in serum levels of laboratory measured values for patients treated with percutaneous transportal sclerotherapy after six months.Kwak et al.
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Fig. 2. 69-year-old man with severe gastric varices draining into large pericardiophrenic vein.
A. Contrast-enhanced CT scan shows large gastric fundal varices (arrows) without portosystemic shunts (not shown). 
B. Contrast-enhanced CT scan shows draining vein of pericardiophrenic vein draining into coronary sinus (arrows).
C. Posterior gastric venogram shows large gastric varices (arrows) draining into pericardiophrenic veins (open arrows).
D. After microcatheter was placed into posterior gastric vein (afferent vein) and pericardiophrenic vein (drainage vein), 19 coils were placed
(arrows). NBCA-Lipiodol mixture was injected via microcatheter after reduction of blood flow. Embolization with additional coils and
injection of NBCA-Lipiodol mixture were performed in left gastric veins and short gastric veins (afferent veins).
E. CT scan obtained six months after treatment shows complete obliteration of varices (arrows).
F. Follow-up CT scan obtained six months later shows complete obstruction of draining vein due to presence of coils and NBCA-Lipiodol
mixture (arrows).
EFAggravation of esophageal varices was observed in four
patients and the patients were treated by endoscopic
sclerotherapy. Ascites were detected in two patients and
pleural effusion was detected in two patients. However,
these complications were temporary.
Changes in the serum levels of laboratory parameters of
the patients are presented in Table 3. The serum albumin
level increased and the ammonia level decreased at six
months (p < 0.05). A significant increase in the prothrom-
bin time was observed at six months (p < 0.05). Significant
changes were not seen in the bilirubin level.
DISCUSSION
The majority of gastric varices that are located at the
fundus drain into the inferior pherenic vein, which later
joins with the left renal vein to form the gastrorenal shunt
or with the inferior vena cava just below the diaphragm to
form the gastrocaval shunt (20, 24). The BRTO procedure
was introduced based on obliteration for a portal-systemic
venous shunt. Since its introduction by Kanagawa et al.
(15), BRTO has become widely accepted as a minimally
invasive, highly effective treatment for gastric varices (15-
23). However, a few gastric varices cases without catheter-
izable main draining veins cannot be treated by BRTO.
These patients can be considered for treatment with
procedures such as endoscopic sclerotherapy, the use of a
TIPS or percutaneous transhepatic sclerotherapy.
Endoscopic injection of NBCA is the only endoscopic
treatment that has been shown as effective for gastric
varices (4-6). The efficacy of endoscopic sclerotherapy for
the initial hemostasis of gastric variceal bleeding has been
reported as 83-100%; however, relatively high rates of
rebleeding (20-25%) have also been reported (4-6). The
occurrence of systemic embolization with NBCA injection
has also been reported (6-9). Risk factors include a large
volume injection and the existence, albeit rare, of shunts
between the portal system and the pulmonary vein.
However, although systemic embolization following
endoscopic injection of NBCA in patients without a porto-
systemic shunt is a rare event, rebleeding of gastric varices
remains a limitation of the use of endoscopic sclerother-
apy.
A TIPS has been widely used to treat patients suffering
with variceal bleeding or refractory ascites from portal
hypertension (25, 26). Tripathi et al. (27) performed a
comprehensive retrospective study of the use of a TIPS for
the prevention of esophageal varices and gastric varices
from rebleeding. The overall survival rates after the use of
TIPS were significantly better for gastric varices as
compared with esophageal varices, and no difference was
seen between patients with gastric varices and patients
with esophageal varices with regard to the rebleeding rates
(20%). The incidence of new-onset encephalopathy was
17% and the cumulative incidence of shunt insufficiency
was approximately 50%. Therefore, the main drawback of
the use of a TIPS is its poor primary patency rate and an
intractable hepatic encephalopathy due to the increased
shunt volume.
Ninoi et al. (22) performed percutaneous transhepatic
sclerotherapy in patients with gastric varices without a
gastrorenal shunt, in patients with gastric varices with a
gastrorenal shunt and gastrocaval shunts and in patients
with gastric varices not treatable by BRTO. This study
described coil embolization of the afferent veins and the
use of 5% ethanolamine oleate with iopamidol (EOI) as the
sclerosant. However, 5% EOI cannot be used in patients
who retain contrast due to the complete occlusion of
afferent veins. Therefore, gastric varices without a
portosystemic shunt had multiple afferent veins, and
complete obliteration of the afferent veins by the use of
coils is very difficult to achieve. Recently, Kiyosue et al.
(24) reported the use of transportal intravariceal
sclerotherapy with NBCA for gastric varices. For
transportal intravariceal sclerotherapy, the NBCA-Lipiodol
mixture is injected via a microcatheter in the varices with
flow control coils placed in the afferent and drainage vein,
which can fill all of the varices and completely obliterate
the varices. Although this study was performed using
transhepatic sclerotherapy in a small number of patients,
follow-up gastroendoscopy showed either the disappear-
ance or a marked decrease of the varices and neither
recurrent gastric varices nor variceal bleeding were
observed during the follow-up period. In our study,
percutaneous transportal sclerotherapy with use of the
NBCA-Lipiodol mixture and microcoils immediately
showed a high success rate. In addition, the presence of
gastric varices was not seen for all of the patients on
follow-up endoscopy. In addition, rebleeding of the gastric
varices did not occur.
The augmentation of portal blood flow with the use of
BRTO can improve liver function, but the use of a TIPS
results in decreased portal flow, leading to deterioration of
the liver function (22, 23). Kiyosue et al. (24) have
reported that the results of hepatic function tests did not
improvet after transportal intravariceal sclerotherapy.
However, in our study, percutaneous transportal
sclerotherapy was followed by an improvement in liver
function. An increase in portal flow, induced by the
obliteration of the large gastric varices, may contribute to
the improvement in liver function seen after transportal
sclerotherapy.
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worsening of esophageal varices due to elevated portal
pressure after treatment (15, 17, 20-22). However, the
worsened esophageal varices, as in this study, could be
successfully treated endoscopically. The presence of ascites
and pleural effusion are complications caused by elevated
portal pressure (20-22). In our study, ascites was detected
in one patient and pleural effusion was detected in two
patients. However, these complications were only
temporary.
A potential risk of the use of the percutaneous
transportal approach is a risk of the peritoneal hemorrhage
during and after the procedure. Transjugular sclerotherapy
with a TIPS approach can be considered as an alternative
approach in patients with ascites and a bleeding diathesis.
In addition, the technique is invasive as compared with
endoscopic injection or BRTO, but it has an advantage
over endoscopic injection of NBCA as flow from the
varices to the shunt can be controlled with the use of coil
embolization of the afferent vein and draining vein prior to
injection. Therefore, this technique carries less risk of
migration of NBCA into the systemic vein, which could
cause a fatal pulmonary embolism, than the use of an
endoscopic injection. Most gastric varices are formed by
the left gastric, posterior gastric or short gastric veins (28,
29) and have multiple small branches that are connected
with the main afferent veins. Therefore, multiple
procedures are needed until the entire variceal complex is
opacified. In our study, the number of small afferent
branches obliterated with use of the NBCA-Lipiodol
mixture ranged from one to six (mean, 4.2).
This study has some limitations. One limitation is that the
study consited of a very small population. BRTO is the first
choice of treatment for gastric varices if this procedure is
possible. If BRTO is not possible, then percutaneous
transportal sclerotherapy is an additional option for the
treatment of gastric varices. Another limitation of the
study is the lack of long-term follow-up after two years.
In conclusion, BRTO can effectively control gastric
varices in patients with a portosystemic shunt. However,
the use of BRTO is limited for patients without catheteriz-
able main draining veins. Although the number of patients
included in this study was small, we have demonstrated
that gastric varices with can be also successfully treated
with percutaneous transportal sclerotherapy and liver
function can be improved. Therefore, percutaneous
transportal sclerotherapy with NBCA is a good alternative
treatment for patients with gastric varices without catheter-
izable main draining veins. However, further studies with a
larger number of patients are required to confirm the
findings.
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